Preclinical investigations on broccoli-derived sulforaphane for the treatment of ophthalmic disease.

Faith A A Kwa, Bang V Bui, Bruce R Thompson, Lauren N Ayton

Journal: Drug discovery today 2023;28(9):103718

PMID: 37467881

Free Full Text on Elsevier Science View on PubMed

Abstract

Vision loss causes a significant burden on individuals and communities on a financial, emotional and social level. Common causes include age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and retinitis pigmentosa (RP; also known as 'rod-cone dystrophy'). As the population continues to grow and age globally, an increasing number of people will experience vision loss. Hence, there is an urgent need to develop therapies that can curb early pathological events. The broccoli-derived compound, sulforaphane (SFN), is reported to have multiple health benefits and modes of action. In this review, we outline the preclinical findings on SFN in ocular diseases and discuss the future clinical testing of this compound.

Address: Department of Health Sciences and Biostatistics, School of Health Sciences, Swinburne University of Technology, Hawthorn, VIC 3122, Australia. Electronic address: [email protected].; Department of Optometry & Vision Sciences, Faculty Medicine, Dentistry & Health Sciences, The University of Melbourne, VIC 3010, Australia.; School of Health Sciences, Faculty Medicine, Dentistry & Health Sciences, The University of Melbourne, VIC 3010, Australia.; Department of Optometry & Vision Sciences, Faculty Medicine, Dentistry & Health Sciences, The University of Melbourne, VIC 3010, Australia; Department of Surgery (Ophthalmology), Faculty Medicine, Dentistry & Health Sciences, The University of Melbourne, VIC 3010, Australia; Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC 3002, Australia.

DOI: 10.1016/j.drudis.2023.103718